drugset / Trial / NCT02459977

The Usefulness of Tacrolimus Without Basiliximab in Well Matched Living Renal Transplantation in Korea

NCT02459977

Unknown 40 enrolled Asan Medical Center
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Basiliximab has been a routine induction therapeutic agent even for well-matched living kidney transplantation(KT) with tacrolimus-based immunosuppression in Korea. As tacrolimus is a different drug from cyclosporine, the investigators study the usefulness of tacrolimus-based immunosuppression without basiliximab in well matched living KT.

Timeline

Start
2012-04
Primary completion
2015-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Basiliximab Monoclonal antibody

Indications

No indication recorded.